10X Genomics Inc reports results for the quarter ended June 30 - Earnings Summary

• 10X Genomics Inc TXG.OQ reported quarterly adjusted earnings of 28 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -45 cents to -30 cents per share.

• Revenue rose 12.9% to $172.91 million from a year ago; analysts expected $139.43 million.

• 10X Genomics Inc's reported EPS for the quarter was 28 cents​.

• The company reported quarterly net income of $34.54 million.

• 10X Genomics Inc shares had risen by 9.3% this quarter and lost 11.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for 10X Genomics Inc is $14.00, about 8.6% above its last closing price of $12.80

This summary was machine generated from LSEG data August 8 at 03:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)